课题基金 / 基金详情

PPARGamma in Sepsis-Induced Immunosuppression

PPARGamma in Sepsis-Induced Immunosuppression
PPARGamma 在脓毒症引起的免疫抑制中的作用
批准号:
7107163
负责人:
RAJU C REDDY
金额:
$13.27万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-30 至 2008-02-29

项目摘要

项目成果

RAJU C REDDY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Patients with sepsis are highly susceptible to the development of nosocomial infection, particularly bacterial infection of the lung. While the exact mechanism(s) that contribute to sepsis-mediated immunosuppression remains unclear, dysregulation of monocyte/macrophage function is believed to play an important role in these phenomena. Recently, peroxisome proliferator-activated receptor-gamma (PPARy), a member of the nuclear receptor superfamily of ligand-dependent transcription factors, has been shown to inhibit the expression of inflammatory mediators from monocytes/macrophages and other leukocyte populations. The hypothesis of this proposal is that sepsis induced immunosuppression is mediated, in part, by PPARy. Furthermore, we postulate that inhibition of this ligand dependent transcription factor will reverse sepsis-induced changes in alveolar macrophage function, resulting in augmented lung antibacterial host defense. A murine model of cecal ligation and puncture (resulting in an abdominal sepsis syndrome) will be utilized to assess the following Specific Aims: I) to determine the time course and magnitude of PPARy expression in lung during the evolution of murine abdominal sepsis; II) to determine the functional significance of PPARy activation on effector cell functions of primary murine alveolar macrophages or murine alveolar macrophage cell lines; III) to identify the endogenous signals that regulate PPARy expression during the evolution of murine abdominal sepsis; and IV) to determine the effect of inhibition of PPARy on sepsis- induced alterations in alveolar macrophage function ex-vivo and susceptibility to Pseudomonas pneumonia in-vivo. Performance of the studies outlined will help define the role of PPARy as a mediator of sepsis-induced alveolar macrophage dysfunction, and may lead to the development of novel therapies to be employed in the treatment of patients with sepsis.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1186/1465-9921-8-90
发表时间: 2007-12-04
期刊: Respiratory research
影响因子: 5.8
作者: [Narala VR, Ranga R, Smith MR, Berlin AA, Standiford TJ, Lukacs NW, Reddy RC]
通讯作者: Reddy RC
DOI: 10.1016/j.pep.2006.08.013
发表时间: 2007-03
期刊: Protein expression and purification
影响因子: 1.6
作者: [P. K. Reddy;Srinivasa G Reddy;V. Narala;S. Majee;Sudhakar Konda;S. Gunwar;Raju C Reddy]
通讯作者: P. K. Reddy;Srinivasa G Reddy;V. Narala;S. Majee;Sudhakar Konda;S. Gunwar;Raju C Reddy
DOI: 10.1016/j.jaci.2008.12.018
发表时间: 2009-03
期刊: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
影响因子: 14.2
作者: [Khan, Farah I., Reddy, Raju C., Baptist, Alan P.]
通讯作者: Baptist, Alan P.
DOI: --
发表时间: 2009-04
期刊: Gene therapy & molecular biology
影响因子: --
作者: [V. Narala;Monica R. Smith;R. K. Adapala;Rajesh Ranga;K. Panati;B. Moore;T. Leff;V. D. Reddy;A. K. Kondapi;Raju C Reddy]
通讯作者: V. Narala;Monica R. Smith;R. K. Adapala;Rajesh Ranga;K. Panati;B. Moore;T. Leff;V. D. Reddy;A. K. Kondapi;Raju C Reddy
Nur77: Novel Mechanistic Insights and Activation in COPD
  • 批准号:
    10513286
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2021
  • 负责人:
    RAJU C REDDY
  • 依托单位:
Airway Epithelial Cell Farnesoid X Receptor in COPD Pathophysiology
PPAR-delta as a Novel Therapeutic Target in Asthma
PPAR-delta as a Novel Therapeutic Target in Asthma
海外基金